APR-246, a small molecule mutant p53 reactivator is currently leading the way and is being studied in five clinical trials (phase 1–2) in various solid organ cancers (ovarian, esophagus, melanoma) but none in breast cancer. The gene discussed is TP53; the disease is melanoma.